Author

Moshe Oren

Weizmann Institute of ScienceORCID 0000-0003-4311-7172Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Moshe Oren1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

Eviatar WeizmaniD· 2 shared Almut SchulzeiD· 1 shared An Nhien TruongiD· 1 shared Angelika Wörner· 1 shared Arturo Simoni NievesiD· 1 shared Ashish NoronhaiD· 1 shared Birgitta E. MichelsiD· 1 shared Boobash-Raj Selvadurai· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Eviatar WeizmanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyClinical EpigeneticsPeer-reviewedApr 29, 2026

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer

Janina Müller, Emre Sofyalı, Luisa E. Schwarzmüller…·Stefan Wiemann

This study identifies GLYATL1 as a mediator of endocrine resistance in luminal breast cancer by promoting metabolic and epigenetic changes that counteract estrogen deprivation.

3 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 23, 2025

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

Rishita Chatterjee, Arturo Simoni Nieves, An Nhien Truong…·Yosef Yarden

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

1 citation

𝕏 PostBluesky